- Home
- Companies
- netherlands
- hematology malignancies
Refine by
Hematology Malignancies Suppliers Serving Netherlands
14 companies found
based inShirley, NEW YORK (USA)
CD Formulation is a leading manufacturer of excipients, serving the pharmaceutical industry to help it improve the performance of its products. We develop, produce and sell pharmaceutical excipients for solid, semi-solid and liquid dosage forms. Our ...
Bendamustine hydrochloride monotherapy or combination therapy has been designated by European and American clinical guidelines as a first - or second-line treatment option for a variety of hematological ...
based inCambridge, UNITED KINGDOM
Our business is organised to deliver our strategic priorities sustainably, supporting continued scientific innovation and commercial success. We focus on the discovery, development and commercialisation of prescription medicines in Oncology and ...
Mechanism: BCL2/xL; Area under investigation: haematological malignancies; Date commenced phase: Q4 2019; Estimated Filing Acceptance: US: EU: Japan: China; Additional information: Partnered product. Molecule size: Small molecule; Status ...
based inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
TP-3654 is an oral investigational inhibitor of PIM kinases, which has potential antitumor and anti-fibrotic effects through multiple pathways, including induction of ...
based inUtrecht, NETHERLANDS
At LAVA, we are focused on applying our expertise in gamma-delta T cell engagers. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor ...
based inCambridge, MASSACHUSETTS (USA)
Foundation Medicine was founded in 2010 with a mission to bring deep molecular information to the point of care for every patient living with advanced cancer. We’re an essential partner to patients, physicians, researchers, and biopharma ...
Discover tissue AND blood-based FDA-approved comprehensive genomic profiling testing for all solid tumors with FoundationOne®CDx and FoundationOne®Liquid CDx. In addition, FoundationOne®Heme is a laboratory developed test for ...
based in, MASSACHUSETTS (USA)
Thermo Scientific instruments, equipment, software, services and consumables empower scientists to solve for complex analytical challenges in pharmaceutical, biotechnology, academic, government, environmental and industrial research, as well as the ...
based inChangning District, CHINA
Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative ...
Clinical manifestations of MM include hypercalcemia, renal insufficiency, anemia, and the destruction of the bone. 1,2 MM primarily occurs in the elderly population. In the Chinese population, MM is the second most common ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and ...
based inSan Diego, CALIFORNIA (USA)
Invivoscribe is a global leader in molecular diagnostics, providing a comprehensive range of standardized, CE-marked in vitro diagnostic products and companion diagnostics for hematology-oncology. The company's offerings include research use only ...
based inMilford, MASSACHUSETTS (USA)
SeraCare is a leading partner and supplier of diagnostic quality controls, biological materials, and reagents to in vitro diagnostics developers, clinical laboratories, and life science researchers worldwide. Since the early 1980s, we have supported ...
based inAmsterdam, NETHERLANDS
Founded in 1997, Kiadis Pharma is a fully integrated biopharmaceutical company committed to developing innovative, personalized, next-generation cell-based immunotherapies for patients with life threatening diseases. With headquarters in Amsterdam, ...
Ushering in the Future of NK-cell Therapy: Natural killer (NK) cells have long been known to play a significant role in the body’s innate immune response. They were first described in the 1970s, but only in the last 15 years has significant ...
based inRockville, MARYLAND (USA)
Since the treatment of our first oncology patient in 2015, AbelZeta has been able to build best-in-class and best-in-disease potential pipeline, leading to the licensing of two CD20-directed autologous CAR-Ts to Janssen Biotech in 2023. Our goal is ...
PRODUCT: C-CAR066. INDICATION: r/r B-NHL. PLATFORM: CAR-T. PRECLINICAL: CD20. IIT²: - PHASE 1/1B: - PHASE 2: - PARTNERS: Johnson & ...
based inCopenhagen V, DENMARK
Founded in 1999 in Copenhagen, Denmark, we are a dual-listed, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. We are led by an experienced ...
In June 2019, Genmab entered into an exclusive worldwide license and option agreement with Janssen Biotech Inc. to develop and commercialize HexaBody®-CD38. In preclinical models of hematological malignancies, ...
based inMunich, GERMANY
Therawis Pharma GmbH is a privately held, profitable oncology-specialized company with offices located in Munich, Germany, and was founded in April 2014. We provide european-wide support in medical & clinical trial development for therapeutics and ...
Personalized medicine aims to identify patients who require treatment and subsequently select the right therapy based on individual factors and tumor characteristics, i.e. personalized medicine targets to identify the right patients for the right ...